Skip to main content
< Back to news
 06.05.2025

Jordi Fàbrega, CEO of Connecta Therapeutics: “The PCB is a hub of excellence in biosciences, where research and development thrive, and that’s why we feel so aligned with it”

Connecta Therapeutics is a biotechnology company focused on developing new drugs for unresolved diseases of the central nervous system, with an emphasis on neurodevelopmental disorders. In this interview, Jordi Fàbrega, co-founder and CEO of Connecta Therapeutics, talks to us about their most advanced programme for Fragile X syndrome, a genetic disorder currently without a curative treatment.

It is a small molecule, first-in-class, with properties that can model neuroplasticity, aimed at Fragile X syndrome. The drug is currently in clinical phases, and in 2025, Phase II will begin in adults, with plans to expand to the paediatric population. This molecule, with an innovative mechanism of action, not only addresses Fragile X syndrome but also offers the potential to treat other rare, incurable diseases, as it functions as a therapeutic platform that could be extended to other indications.

For Connecta Therapeutics, the Barcelona Science Park (PCB) represents a centre of excellence in knowledge and innovation in biosciences. The atmosphere at the PCB fosters research and development with a high level of commitment, making the company feel comfortable and well-aligned with its surroundings.